Residual Tumor and Response to Treatment (RT2Lab)

Neoadjuvant treatment (i.e treatment before surgery) represents an opportunity to study and monitor “in vivo” treatment-sensitivity of the tumor. It enables leveraging the potential of clinical research in breast cancer and represents per se the optimal framework for translational research. By applying strategies inspired from radiotherapy, immunotherapy, genetics and epigenetics etc… a wide variety of treatments can be evaluated and monitored.